Lecanemab, marketed as Leqembi, is a monoclonal antibody therapy for Alzheimer’s illness that targets and removes dangerous amyloid plaques whereas slowing cognitive decline. Scientists from VIB and KU Leuven have now uncovered precisely the way it works. Their analysis exhibits {that a} particular a part of the antibody, often known as the ‘Fc fragment’, is essential for activating microglia — the immune cells of the mind -, which then start clearing these poisonous deposits. This examine offers the primary clear clarification of how this kind of remedy capabilities, resolving long-standing questions and providing steering for creating safer and more practical Alzheimer’s therapies. The findings had been revealed in Nature Neuroscience.
“Our examine is the primary to obviously show how this anti-amyloid antibody remedy works in Alzheimer’s illness. We present that the remedy’s efficacy depends on the antibody’s Fc fragment, which prompts microglia to successfully clear amyloid plaques,” says Dr. Giulia Albertini, co-first creator of the examine. “The Fc fragment works as an anchor that microglia latch onto when they’re close to plaques, as a consequence of which these cells are reprogrammed to clear plaques extra effectively.”
Alzheimer’s Illness and the Position of Microglia
Greater than 55 million folks worldwide reside with Alzheimer’s illness, which is pushed by the buildup of amyloid plaques within the mind. These poisonous protein clusters harm neurons and finally result in dementia. Though microglia naturally collect round these plaques, they’re usually unable to take away them successfully. In response, researchers have been creating therapies aimed toward restoring this important immune perform.
Antibody Remedy and the Fc Fragment
Lecanemab is likely one of the therapies designed to focus on amyloid-beta plaques and sluggish illness development, and it has already obtained FDA approval. Nonetheless, unintended effects have restricted its general profit, and till now, its actual mode of motion remained unclear.
Antibodies are made up of two principal elements. One half binds to a selected goal similar to amyloid plaques, whereas the opposite half, the Fc fragment, alerts the immune system. Earlier analysis steered that microglia play a job in clearing plaques, however direct proof linking their exercise to lecanemab’s effectiveness was lacking. Some scientists had additionally proposed that plaque elimination may happen with out involvement of the Fc fragment. The staff led by Prof. Bart De Strooper demonstrated that this fragment is crucial, as microglia solely responded when it was intact and practical.
To analyze this, researchers used a specifically designed Alzheimer’s mouse mannequin that included human microglial cells. This allowed them to carefully observe how lecanemab interacts with human immune cells and promotes plaque clearance. When the Fc fragment was eliminated, the antibody not had any impact.
“The truth that we used human microglia inside a managed experimental mannequin was a significant energy of our examine. This allowed us to check the very antibodies utilized in sufferers and observe human-specific responses with unprecedented decision,” provides Magdalena Zielonka, co-first creator.
Contained in the Mind’s Plaque-Clearing Course of
The staff then examined how activated microglia really take away amyloid plaques on this hybrid mannequin. They recognized key mobile processes concerned on this cleanup, together with phagocytosis and lysosomal exercise. These processes had been solely triggered when the Fc fragment was current. With out it, the microglia remained inactive.
Utilizing superior strategies similar to single-cell and spatial transcriptomics, the researchers additionally recognized a selected gene exercise sample in microglia related to efficient plaque elimination. This sample included sturdy expression of the gene SPP1 and was uncovered utilizing NOVA-ST, a technique developed by the Stein Aerts lab (VIB-KU Leuven).
Towards Safer and Extra Efficient Alzheimer’s Remedies
By defining the precise microglial program liable for clearing plaques, the findings level towards new methods for treating Alzheimer’s illness. Future therapies could possibly activate microglia straight, with out counting on antibodies.
“This opens doorways to future therapies that will activate microglia with out requiring antibodies. Understanding the significance of the Fc fragment helps information the design of next-generation Alzheimer’s medication,” concludes Prof. Bart De Strooper.
The analysis performed on the VIB-KU Leuven Heart for Mind & Illness Analysis was supported by the European Analysis Council (ERC), Alzheimer’s Affiliation USA, Analysis Basis Flanders (FWO), Queen Elisabeth Medical Basis for Neurosciences, Stichting Alzheimer Onderzoek — Fondation Recherche Alzheimer (STOPALZHEIMER.BE), KU Leuven, VIB, and UK Dementia Analysis Institute College School London.
